💊 Drugs A-Z 🧬 Targets 🛠 Tools 📚 Guides
All Drugs Drug Classes Therapeutic Areas Side Effects
Guides Glossary Timeline
Comparisons Drug Journeys Drug Families
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Samarium Sm 153 Lexidronam Pentasodium

CHEMBL2096660 Phase 4 Approved Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
695.9 g/mol
LogP
—
Phase
4

Samarium Sm-153 lexidronam pentasodium is the radioactive form of samarium lexidronam, in which samarium-153 is chelated to EDTMP for targeted bone palliation in patients with osteoblastic metastases from breast, prostate, and other cancers. The beta-emitting isotope concentrates in hydroxyapatite-rich metastatic bone lesions, delivering localized radiation to reduce skeletal pain and tumor burden. See samarium lexidronam pentasodium for complete pharmacological details.

Molecular Weight

695.9300 g/mol

TPSA

259.00 Ų

Therapeutic Areas

Breast Cancer Chronic Pain Pain Management Prostate Cancer

Mechanism of Action

Forms stable, water-soluble chelate complexes with specific metal ions, facilitating their excretion from the body through the kidneys. This reduces toxic metal burden in affected tissues.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanism

Forms stable, water-soluble chelate complexes with specific metal ions, facilitating their excretion from the body through the kidneys. This reduces toxic metal burden in affected tissues.

SMILES

C(CN(CP(=O)([O-])[O-])CP(=O)([O-])[O-])N(CP(=O)([O-])[O-])CP(=O)([O-])[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[153Sm+3]

InChI

InChI=1S/C6H20N2O12P4.5Na.Sm/c9-21(10,11)3-7(4-22(12,13)14)1-2-8(5-23(15,16)17)6-24(18,19)20;;;;;;/h1-6H2,(H2,9,10,11)(H2,12,13,14)(H2,15,16,17)(H2,18,19,20);;;;;;/q;5*+1;+3/p-8/i;;;;;;1+3

Molecular Formula

C6H12N2Na5O12P4Sm

HBD / HBA

- / 14

Rotatable Bonds

7

Heavy Atoms

30

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

Samarium Sm-153 lexidronam pentasodium is the radioactive form of samarium lexidronam, in which samarium-153 is chelated to EDTMP for targeted bone palliation in patients with osteoblastic metastases from breast, prostate, and other cancers. The beta-emitting isotope concentrates in hydroxyapatite-rich metastatic bone lesions, delivering localized radiation to reduce skeletal pain and tumor burden. See samarium lexidronam pentasodium for complete pharmacological details.

Forms stable, water-soluble chelate complexes with specific metal ions, facilitating their excretion from the body through the kidneys. This reduces toxic metal burden in affected tissues.

Yes, Samarium Sm 153 Lexidronam Pentasodium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2096660. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 9810246. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.